Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health, Inc. affiliate filed a Form 144 reporting the proposed sale of 2,000 shares of common stock on 06/24/2026 associated with an employee stock option exercise and a broker payment for a cashless exercise. The filing also lists prior sales by Meghan V. Joyce of 10,000 shares on 06/03/2026 for $1,269,809.00 and 6,203 shares on 06/22/2026 for $812,604.00. Shares outstanding are shown as 132,599,929 as of 06/24/2026.
Guardant Health director Tariq Musa sold 1,951 shares of Common Stock in an open-market transaction. The shares were sold at an average price of $131.16 per share. After this sale, Musa directly holds 11,048 Guardant Health shares, indicating he retains a significant ongoing equity position in the company.
Guardant Health, Inc. director Myrtle S. Potter reported an open-market sale of Common Stock. She sold 1,556 shares on June 22, 2026 at an average price of $131.16 per share. After this transaction, she directly holds 20,971 Guardant Health shares.
Guardant Health director Roberto Mignone reported routine equity compensation activity, exercising restricted stock units (RSUs) into common shares. On May 21, 2026 and June 21, 2026, RSU conversions of 264 shares each delivered a total of 528 common shares at a stated price of $0.00 per share.
After these transactions, Mignone directly held 9,482 shares of Guardant Health common stock and 7,392 RSUs. Footnotes explain that the RSU award was granted on November 8, 2024 and vests over four years, with 25% vesting on October 21, 2025 and the remaining 75% vesting monthly over the following three years.
Guardant Health director Tariq Musa reported routine equity compensation activity. On June 17, 2026, he exercised 4,203 Restricted Stock Units into the same number of common shares following full vesting tied to the 2026 Annual Meeting of Stockholders.
He also received a new grant of 2,711 Restricted Stock Units that will vest in full on the one-year anniversary of the grant date, June 17, 2026, or on the date of Guardant Health’s next annual meeting of stockholders, whichever is earlier. Following these transactions, Musa directly holds 12,999 shares of common stock and 2,711 Restricted Stock Units, with no shares sold.
Guardant Health director Myrtle S. Potter reported routine equity compensation activity. On June 17, 2026, she exercised 4,203 Restricted Stock Units, acquiring the same number of common shares and bringing her direct common stock holdings to 22,527 shares. A prior restricted stock unit award vested in full on the 2026 Annual Meeting date. She also received a new grant of 2,711 Restricted Stock Units, which will vest in full on the earlier of the one-year anniversary of the June 17, 2026 grant date or the company’s next annual meeting of stockholders.
Guardant Health director Roberto Mignone reported routine equity compensation activity. On June 17, 2026, he exercised restricted stock units covering 4,203 shares of Common Stock, bringing his direct Common Stock holdings to 8,954 shares after the transaction.
On the same date, he received a new grant of 2,711 Restricted Stock Units, each representing a right to receive one share of Common Stock. According to the footnotes, the RSU award that generated the 4,203 shares vested in full on the date of the 2026 Annual Meeting of Stockholders, while the new 2,711-unit award will vest in full on the earlier of the one-year anniversary of its June 17, 2026 grant date or the Company’s next annual meeting of stockholders.
Guardant Health director Steve E. Krognes reported equity compensation activity. On June 17, 2026, 4,203 Restricted Stock Units fully vested in connection with the company’s 2026 Annual Meeting of Stockholders and were converted into an equal number of shares of common stock.
Following this derivative exercise, Krognes held 14,425 shares of Guardant Health common stock directly. On the same date, he also received a new grant of 2,711 Restricted Stock Units, each representing a right to receive one share of common stock that will vest in full on the earlier of June 17, 2027 or the company’s next annual stockholder meeting.
Guardant Health, Inc. director Meghan V. Joyce reported the vesting and settlement of a restricted stock unit award into common stock. On June 17, 2026, coinciding with the company’s 2026 Annual Meeting of Stockholders, 4,203 restricted stock units converted into 4,203 shares of common stock at no exercise price. Following this compensation-related transaction, Joyce directly holds 15,386 shares of Guardant Health common stock, and no open-market purchases or sales were reported in this filing.
Guardant Health director Manuel Hidalgo Medina reported compensation-related equity activity on June 17, 2026. He exercised vested restricted stock units to acquire 4,435 shares of Common Stock at a conversion price of $0.00 per share and received a new grant of 2,711 restricted stock units. Following these transactions, one reported line shows direct ownership of 5,074 Common Stock shares and 2,711 restricted stock units, reflecting routine vesting and grants rather than open-market trading.